UNSPSC 51151617: Biperiden

This classification denotes an antiparkinsonian agent and antimuscarinic agent with the molecular formula C21H29NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K35N76CUHF, chemically known as 5-norbornene-2-methanol, alpha-phenyl-alpha-(2-piperidinoethyl)- but generally known as biperiden hydrochloride, which bears US NIH Compound Identifier 2381. European Medicines Agency schedules Biperiden hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00807MIG.

Most nations schedule biperiden under HS 29333999 and SITC 51574. As of Q4 2014, BIPERIDEN remains the US FDA Preferred Term for this commodity. Biperiden bears US NLM identifiers UMLS ID C0005578 and NCI Concept Code C65263. SMILES: OC(C1C2CC(C1)C=C2)(CCN1CCCCC1)C1CCCCC1.

UNSPSC 51151617 Biperiden is a Commodity code that nominally covers a specific pharmaceutical product, but the recent state and local solicitations tagged under it reflect broader emergency-response and pharmacy-benefit procurement activity rather than biperiden itself. Seminole County, Florida is procuring naloxone and drug deactivation systems through an IFB (Solicitation IFB60459723LAS, response due July 26, 2023), while the Texas Health and Human Services Commission has issued an RFI to explore direct-to-manufacturer prescription programs. State and local health departments, county public health agencies, and state HHS commissions are the primary issuing bodies pursuing opportunities under or near this code, with activity driven by opioid-response initiatives and pharmacy-benefit modernization. The scope of actual work diverges significantly from the code's abstract pharmaceutical designation — recent procurements center on naloxone distribution networks, drug-disposal systems, and strategic pharmacy contracting arrangements rather than biperiden supply.

Activity is concentrated in Florida and Texas based on recent postings. Seminole County's naloxone procurement calls for 1,900 units annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, on a two-year initial term with one-year renewal option; the contract is potentially FEMA-funded and requires E-Verify compliance, drug-free workplace certification, and standard commercial insurance coverage. Texas HHS's RFI is exploratory, seeking vendor capacity for direct contracting with manufacturers outside traditional pharmacy benefit manager and wholesaler channels, with no formal response deadline or evaluation timeline specified as of the April 3, 2026 posting. The code shows limited recent activity overall, and the mismatch between its nominal scope (a specific anticholinergic medication) and the emergency-response and pharmacy-system-redesign work actually being solicited suggests this code is either infrequently used for direct purchases of the named drug or is being applied inconsistently by issuing bodies.